Drug-drug interaction with statins

Expert Review of Clinical Pharmacology

Volumn 1, Issue 1, 2008, Pages 105-113

  Corsini, Alberto ^a   Bellosta, Stefano ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; ANTIFUNGAL AGENT; ANTILIPEMIC AGENT; ATORVASTATIN; BILE ACID SEQUESTRANT; CYCLOSPORIN A; DICLOFENAC; DILTIAZEM; EZETIMIBE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MACROLIDE; MEVINOLIN; MIBEFRADIL; NEFAZODONE; NELFINAVIR; NICOTINIC ACID; PRAVASTATIN; PROTEINASE INHIBITOR; RESIN; RITONAVIR; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG; VERAPAMIL; WARFARIN;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EVENING DOSAGE; FOOD; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; GRAPEFRUIT; GRAPEFRUIT JUICE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; LONG TERM CARE; MAXIMUM PLASMA CONCENTRATION; MONOTHERAPY; MYOPATHY; MYOSITIS; PRACTICE GUIDELINE; PRESCRIPTION; REVIEW; RHABDOMYOLYSIS; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 38349026809     PISSN: 17512433     EISSN: None     Source Type: Journal    
DOI: 10.1586/17512433.1.1.105     Document Type: Review

References (63)

1. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360(9326), 7-22 (2002).
2. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106(25), 3143-3421 (2002).
3. Knopp RH. Drug treatment of lipid disorders. N. Engl. J. Med. 341(7), 498-511 (1999).
4. Mahley RW, Bersot TP. Drug therapy for hypercholesterolemia and dyslipidemia. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics. Brunton LL (Ed.). McGraw Hill, NY, USA 933-966 (2005).
5. Bellosta S, Paoletti R, Corsini A. Safety of statins: focus on clinical pharmacokinetics and drug interactions. Circulation 109(23 Suppl. 1), III50-III57 (2004).
6. Corsini A, Bellosta S, Baetta R et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol. Ther. 84(3), 413-428 (1999).
7. Farmer JA, Torre-Amione G. Comparative tolerability of the HMG-CoA reductase inhibitors. Drug Saf. 23(3), 197-213 (2000).
8. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann. Pharmacother. 35(7-8), 908-917 (2001).
9. Ballantyne CM, Corsini A, Davidson MH et al. Risk for myopathy with statin therapy in high-risk patients. Arch. Intern. Med. 163(5), 553-564 (2003).
10. Tobert JA. Efficacy and long-term adverse effect pattern of lovastatin. Am. J. Cardiol. 62(15), J28-J34 (1988).
11. Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. JAMA 289(13), 1681-1690 (2003).
12. Stockley's Drug Interactions. Baxter K (Ed.). Pharmaceutical Press, London, UK (2006).
13. Martin PD, Warwick MJ, Dane AL, Brindley C, Short T. Absolute oral bioavailability of rosuvastatin in healthy white adult male volunteers. Clin. Ther. 25(10), 2553-2563 (2003).
14. Kantola T, Backman JT, Niemi M, Kivisto KT, Neuvonen PJ. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations. Eur. J. Clin. Pharmacol. 56(3), 225-229 (2000).
15. Transon C, Leemann T, Vogt N, Dayer P. In vivo inhibition profile of cytochrome P450TB (CYP2C9) by (±)-fluvastatin. Clin. Pharmacol. Ther. 58(4), 412-417 (1995).
16. Lenhard JM, Croom DK, Weiel JE, Winegar DA. HIV protease inhibitors stimulate hepatic triglyceride synthesis. Arterioscler. Thromb. Vasc. Biol. 20(12), 2625-2629 (2000).
17. Rosenson RS. Current overview of statin-induced myopathy. Am. J. Med. 116(6), 408-416 (2004).
18. Penzak SR, Chuck SK, Stajich GV. Safety and efficacy of HMG-CoA reductase inhibitors for treatment of hyperlipidemia in patients with HIV infection. Pharmacotherapy 20(9), 1066-1071 (2000).
19. Cheng CH, Miller C, Lowe C, Pearson VE. Rhabdomyolysis due to probable interaction between simvastatin and ritonavir. Am. J. Health. Syst. Pharm. 59(8), 728-730 (2002).
20. Corsini A. The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk. Cardiovasc. Drugs Ther. 17(3), 265-285 (2003).
21. Corsini A, Bellosta S, Davidson MH. Pharmacokinetic interactions between statins and fibrates. Am. J. Cardiol. 96(9A), K44-K49 (2005).
22. Shitara Y, Sato H, Sugiyama Y. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45, 689-723 (2005).
23. Kosoglou T, Statkevich P, Johnson-Levonas AO et al. Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions. Clin. Pharmacokinet. 44(5), 467-494 (2005).
24. Lewin JJ 3rd, Nappi JM, Taylor MH. Rhabdomyolysis with concurrent atorvastatin and diltiazem. Ann. Pharmacother. 36(10), 1546-1549 (2002).
25. Azie NE, Brater DC, Becker PA, Jones DR, Hall SD. The interaction of diltiazem with lovastatin and pravastatin. Clin. Pharmacol. Ther. 64(4), 369-377 (1998).
26. Mousa O, Brater DC, Sunblad KJ, Hall SD. The interaction of diltiazem with simvastatin. Clin. Pharmacol. Ther. 67(3), 267-274 (2000).
27. Peces R, Pobes A. Rhabdomyolysis associated with concurrent use of simvastatin and diltiazem. Nephron 89(1), 117-118 (2001).
28. Omar MA, Wilson JP. FDA adverse event reports on statin-associated rhabdomyolysis. Ann. Pharmacother. 36(2), 288-295 (2002).
29. Lau WC, Waskell LA, Watkins PB et al. Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction. Circulation 107(1), 32-37 (2003).
30. Muller I, Besta F, Schulz C et al. Effects of statins on platelet inhibition by a high loading dose of clopidogrel. Circulation 108(18), 2195-2197 (2003).
31. Saw J, Steinhubl SR, Berger PB et al. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial. Circulation 108(8), 921-924 (2003).
32. Serebruany VL, Malinin AI, Callahan KP, Gurbel PA, Steinhubl SR. Statins do not affect platelet inhibition with clopidogrel during coronary stenting. Atherosclerosis 159(1), 239-241 (2001).
33. Saw J, Brennan DM, Steinhubl SR et al. Lack of evidence of a clopidogrel-statin interaction in the CHARISMA trial. J. Am. Coll. Cardiol. 50(4), 291-295 (2007).
34. Kantola T, Kivisto KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin. Pharmacol. Ther. 63(4), 397-402 (1998).
35. Lilja JJ, Kivisto KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin. Pharmacol. Ther. 64(5), 477-483 (1998).
36. Lilja JJ, Kivisto KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68(4), 384-390 (2000).
37. Guo LQ, Ysmazoe Y. Inhibition of cytochrome P450 by furanocoumarins in grapefruit juice and herbal medicines. Acta Pharmacol. Sin. 25(2), 129-136 (2004).
38. Honda Y, Ushigome F, Koyabu N et al. Effects of grapefruit juice and orange juice components on P-glycoprotein- and MRP2-mediated drug efflux. Br. J. Pharmacol. 143(7), 856-864 (2004).
39. Lin JC, Ito MK. A drug interaction between troglitazone and simvastatin. Diabetes Care 22(12), 2104-2106 (1999).
40. Kyrklund C, Backman JT, Kivisto KT et al. Rifampin greatly reduces plasma simvastatin and simvastatin acid concentrations. Clin. Pharmacol. Ther. 68(6), 592-597 (2000).
41. Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80(6), 565-581 (2006).
42. Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol. Ther. 112(1), 71-105 (2006).
43. Murphy MJ, Dominiczak MH. Efficacy of statin therapy: possible effect of phenytoin. Postgrad. Med. J. 75(884), 359-360 (1999).
44. Sugimoto K, Ohmori M, Tsuruoka S et al. Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin. Clin. Pharmacol. Ther. 70(6), 518-524 (2001).
45. Gotto AM Jr. Safety and statin therapy: reconsidering the risks and benefits. Arch. Intern. Med. 163(6), 657-659 (2003).
46. Cilla DD Jr, Gibson DM, Whitfield LR, Sedman AJ. Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening. J. Clin. Pharmacol. 36(7), 604-609 (1996).
47. Hamelin BA, Turgeon J. Hydrophilicity/lipophilicity: relevance for the pharmacology and clinical effects of HMG-CoA reductase inhibitors. Trends Pharmacol. Sci. 19(1), 26-37 (1998).
48. Martin J, Krum H. Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class: are they clinically relevant? Drug Saf. 26(1), 13-21 (2003).
49. Christians U, Jacobsen W, Floren LC. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol. Ther. 80(1), 1-34 (1998).
50. Zhang W, Yu BN, He YJ et al. Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin. Chim. Acta 373(1-2), 99-103 (2006).
51. Poirier A, Funk C, Lave T, Noe J. New strategies to address drug-drug interactions involving OATPs. Curr. Opin. Drug Discov. Devel. 10(1), 74-83 (2007).
52. Heerey A, Barry M, Ryan M, Kelly A. The potential for drug interactions with statin therapy in Ireland. Ir. J. Med. Sci. 169(3), 176-179 (2000).
53. Ho RH, Kim RB. Transporters and drug therapy: implications for drug disposition and disease. Clin. Pharmacol. Ther. 78(3), 260-277 (2005).
54. Ayrton A, Morgan P. Role of transport proteins in drug absorption, distribution and excretion. Xenobiotica 31(8-9), 469-497 (2001).
55. Wang E, Casciano CN, Clement RP, Johnson WW. HMG-CoA reductase inhibitors (statins) characterized as direct inhibitors of P-glycoprotein. Pharm. Res. 18(6), 800-806 (2001).
56. Bizzaro N, Bagolin E, Milani L, Cereser C, Finco B. Massive rhabdomyolysis and simvastatin. Clin. Chem. 38(8 Pt 1), 1504 (1992).
57. Boyd RA, Stern RB, Stewart BH et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J. Clin. Pharmacol. 40(1), 91-98 (2000).
58. Morimoto K, Oishi T, Ueda S et al. A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab. Pharmacokinet. 19(6), 453-455 (2004).
59. Bolego C, Baetta R, Bellosta S, Corsini A, Paoletti R. Safety considerations for statins. Curr. Opin. Lipidol. 13(6), 637-644 (2002).
60. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286(18), 2270-2279 (2001).
61. Mulder AB, van Lijf HJ, Bon MA et al. Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin. Clin. Pharmacol. Ther. 70(6), 546-551 (2001).
62. Bellosta S, Paoletti R, Corsini A. Safety of dyslipidemic agents. In: Comprehensive Management of High Risk Cardiovascular Patients. Gotto AM Jr, Toth PP (Eds). Informa Healthcare USA, Inc., NY, USA 389-407 (2007).
63. Hsiang B, Zhu Y, Wang Z et al. A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274(52), 37161-37168 (1999).